Skip to main content

A case for measuring both cellular and cell-free mitochondrial DNA as a disease biomarker in human blood.

Rosa HS, Ajaz S, Gnudi L, Malik AN

Publication: FASEB J (2020) • Vol 34 • Page 12278-12288PMID: 32729179View on PubMed

Purpose

The authors compared levels of mitochondrial DNA (mtDNA) in whole blood, peripheral blood mononuclear cells (PBMCs), plasma, and serum from healthy individuals and patients with diabetes. The authors also investigated the relationship between mtDNA content of serum or plasma from diabetes patients and patient body mass index (BMI) or cholesterol, glycated hemoglobin (HbA1c), or blood glucose levels.

Conclusion

Quantifiable DNA was obtained from whole blood and PBMC, but the yield from PBMC showed more inter-individual variability. The mitochondrial to nuclear DNA ratio was higher in extracts from PBMC than whole blood but was comparable in both in healthy patients and those with diabetes. Serum had significantly more mtDNA than plasma. The number of copies of mtDNA per µL of serum and plasma were 2.08- and 2.33-fold higher in diabetes patients than healthy controls. In patients where multiple specimen types were collected, the ratio of mitochondrial to nuclear DNA in whole blood was not correlated with the mtDNA content of the PBMCs or serum, nor was there a correlation between mtDNA contents of serum and plasma but the mitochondrial to nuclear DNA ratio in whole blood was weakly negatively correlated with plasma mtDNA content in diabetes patients.

Studies (1)

Purpose

The authors compared levels of mtDNA in whole blood, PBMCs, plasma, and serum from healthy individuals and patients with diabetes. The authors also investigated the relationship between mtDNA content of serum or plasma from diabetes patients and patient BMI or cholesterol, HbA1c, or blood glucose levels. Blood from 23 healthy patients and 20 patients with diabetes (13 type I and 7 Type II) was collected into EDTA Vacutainer Tubes, sodium heparin Mononuclear Cell Preparation Tubes, and/or BD Vacutainer Serum Separation Tubes. Mononuclear Cell Preparation Tubes were inverted 8-10 times and centrifuged at 1800 x g for 20 min at 20°C to separate the cells and PBMC. The plasma was frozen at -80°C and the cells frozen at -80°C after washing in PBS. Blood in BD Vacutainer Serum Separation Tubes was allowed to clot for 30 min before isolation of serum by centrifugation at 1300 x g for 10 minutes at 20°C which was stored frozen at -80°C. DNA was extracted from whole blood in EDTA Vacutainer Tubes and PBMC resuspended in PBS using the QIAamp DNA Mini Kit and diluted based on NanoDrop quantification before sonication. DNA was extracted from plasma and serum using QIAamp MinElute Virus Spin Kit with carrier RNA and sonicated without dilution. mtDNA was quantified by real-time PCR amplification of a non-coding region mtDNA target and normalized to nuclear β2-microglobulin.

Summary of Findings

Quantifiable DNA was obtained from whole blood (19.7 to 53.7 ng) and PBMC (1.6-14.3 µg/per pellet) but the yield from PBMC showed more inter-individual variability. The mitochondrial to nuclear DNA ratio was higher in extracts from PBMC than whole blood (321 ± 130 versus 84 ± 29 mtDNA copies per cell, P<0.0001). Serum had significantly more mtDNA than plasma (914 ± 680 versus 299 ± 182 copies per µL), but also had more nuclear DNA contamination (24 ± 24 versus 6 ± 3 copies per µL). In specimens from the 17 healthy patients where all specimen types were collected, the ratio of mitochondrial to nuclear DNA in whole blood was not correlated with the mtDNA content of the PBMCs, serum, or plasma nor between PBMC ratio of mitochondrial to nuclear DNA and mtDNA contents of serum or plasma.

The mitochondrial to nuclear DNA ratios were comparable in PBMC and whole blood from diabetes patients and the healthy controls and, similar to results for healthy controls, the mitochondrial to nuclear DNA ratio was higher in extracts from PBMC than whole blood (339 ± 159 versus 82 ± 25 mtDNA copies per cell, P<0.0001). In contrast, the number of copies of mtDNA per µL of serum and plasma were 2.08- and 2.33-fold higher in diabetes patients than healthy controls (P=0.0114 and P=0.0018, respectively).  The authors state there was no correlation between mtDNA content of serum or plasma and patient BMI or cholesterol, HbA1c, or blood glucose levels. For the 19 diabetes patients with at least two sample types, there was no correlation between the mitochondrial to nuclear DNA ratio in whole blood and that in PBMCs or mtDNA content of serum but mitochondrial to nuclear DNA ratio in whole blood was weakly negatively correlated with plasma mtDNA content (r2=0.235, P=0.0414).

  • Biospecimens

    FluidBlood
    FluidSerum
    FluidPlasma
    CellWhite Cells
  • Preservation Types

    Frozen
  • Diagnoses

    Diabetes Type 1
    Diabetes Type 2
    Normal
  • Platforms

    DNAReal-time qPCR
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionDiagnosis/ patient condition
    Diabetes (type I or II)
    Healthy
    PreaquisitionPatient body mass index
    27.02 ± 5.11
    PreaquisitionPrognostic factor
    Cholesterol 4.44 ± 0.87
    Glucose not specified
    HbA1c 65.84 ± 15.66
    Biospecimen Aliquots and ComponentsBlood and blood products
    Peripheral blood mononuclear cells
    Plasma
    Serum
    Whole blood
    Real-time qPCR SpecificTargeted nucleic acid
    B2M
    mtDNA